Conspicuously, HSP90 inhibition following PU-H71 treatment was shown to disrupt the chaperone’s interaction with HER2 stimulating its degradation and then reducing its levels in cancer cells (Li and Luo, 2023). Here, HSP90AB1 is linked to cancer.